BUZZ-Invivyd rises as drugmaker starts late-stage trial for COVID prevention antibody** Shares of drugmaker Invivyd IVVD.O rise 1.4% to $2.92 premarket
** Co says it has started late-stage clinical trial to test its experimental COVID-19 antibody, VYD2311, as a preventive treatment for the disease
** Study will enroll 1,770 adults and teens; compare single vs monthly shots to placebo, says co
** IVVD says the goal is to offer vaccine alternative for high-risk people seeking protection
** Top-line results expected by mid-2026 - IVVD
** Up to last close, stock up ~133% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.